Progesterone Receptor Antibody, 100ug

Progesterone receptor (PGR) is a ligand-activated nuclear hormone receptor that regulates transcriptional responses to progesterone signaling in hormone-responsive tissues. Progesterone Receptor Antibody for IHC targets this steroid hormone receptor, also known as PR or Nuclear receptor subfamily 3 group C member 3 (NR3C3). The receptor functions as a nuclear transcription factor that modulates gene expression involved in reproductive biology, endocrine signaling, and hormone-dependent cellular differentiation. In immunohistochemistry studies, Progesterone receptor is typically detected as nuclear staining within epithelial and tumor cells in hormone-responsive tissues.<br><br>Progesterone Receptor Antibody for IHC enables visualization of nuclear Progesterone receptor expression in formalin-fixed paraffin-embedded tissues using immunohistochemistry. In IHC staining, Progesterone receptor appears predominantly as strong nuclear staining because the receptor acts as a DNA-binding transcription factor regulating progesterone-responsive genes. This nuclear staining pattern allows researchers and pathologists to examine receptor expression and distribution directly within tissue architecture.<br><br>PR immunohistochemistry staining is widely used in breast cancer diagnostics to evaluate progesterone receptor expression in tumor epithelial cells. Assessment of PR status by IHC is commonly performed together with estrogen receptor (ER) and HER2 testing to characterize hormone receptor status and guide therapeutic decisions in breast carcinoma. Detection of nuclear PR expression using Progesterone Receptor Antibody for IHC therefore plays an important role in studies of hormone-responsive breast tumors and endocrine signaling pathways.<br><br>Tissue microarray analysis using Progesterone Receptor Antibody for IHC demonstrates strong nuclear staining in hormone-responsive tissues such as breast epithelium, ovarian corpus luteum, and uterine endometrium. In cancer tissue microarrays, strong nuclear staining is observed in subsets of breast carcinoma and gynecologic tumors, consistent with the well-established role of progesterone receptor signaling in hormone-dependent cancers. Many other normal tissues and tumor types show little to no staining, reflecting the restricted expression pattern of the receptor.<br><br>Because progesterone receptor expression is an important biomarker in hormone-responsive malignancies, immunohistochemistry analysis of PR remains widely used in cancer research and diagnostic pathology. Progesterone Receptor Antibody for IHC provides a tool for detecting nuclear PR expression in FFPE tissues and for studying progesterone signaling pathways in endocrine tissues and hormone-responsive tumor models.<br><br>This antibody is also part of a broader collection of <a href='/ihc-antibodies-tissue-microarray-validated.html'>IHC antibodies validated by tissue microarray analysis</a>, supporting consistent staining across normal and cancer tissues.

Specifications